A detailed history of Vident Advisory, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 1,724 shares of BIIB stock, worth $299,613. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,724
Previous 2,392 27.93%
Holding current value
$299,613
Previous $516 Million 22.51%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $127,267 - $158,128
-668 Reduced 27.93%
1,724 $400 Million
Q1 2024

May 14, 2024

SELL
$212.02 - $267.71 $1.41 Million - $1.78 Million
-6,642 Reduced 73.52%
2,392 $516 Million
Q4 2023

Feb 14, 2024

BUY
$222.59 - $267.94 $660,869 - $795,513
2,969 Added 48.95%
9,034 $2.34 Billion
Q3 2023

Feb 21, 2024

SELL
$253.3 - $285.89 $752,047 - $848,807
-2,969 Reduced 32.86%
6,065 $1.56 Billion
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $1.54 Million - $1.73 Million
6,065 New
6,065 $1.56 Billion

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.